Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for chronic lower extremity arteriosclerosis obliterans in elderly patients with type 2 diabetes
ChiCTR2200061096Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pentoxifylline in arteriosclerosis obliterans, sponsored by Beijing Hospital. Primary endpoints: Pain-free walking distance, Maximum walking distance and 3 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
pentoxifylline
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on ChiCTR2200061096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061096.